Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

156 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III study (NEOPAC study).
Heinrich S, Pestalozzi B, Lesurtel M, Berrevoet F, Laurent S, Delpero JR, Raoul JL, Bachellier P, Dufour P, Moehler M, Weber A, Lang H, Rogiers X, Clavien PA. Heinrich S, et al. Among authors: pestalozzi b. BMC Cancer. 2011 Aug 10;11:346. doi: 10.1186/1471-2407-11-346. BMC Cancer. 2011. PMID: 21831266 Free PMC article. Clinical Trial.
Adjuvant treatment of resectable biliary tract cancer with cisplatin plus gemcitabine: A prospective single center phase II study.
Siebenhüner AR, Seifert H, Bachmann H, Seifert B, Winder T, Feilchenfeldt J, Breitenstein S, Clavien PA, Stupp R, Knuth A, Pestalozzi B, Samaras P. Siebenhüner AR, et al. Among authors: pestalozzi b. BMC Cancer. 2018 Jan 11;18(1):72. doi: 10.1186/s12885-017-3967-0. BMC Cancer. 2018. PMID: 29325521 Free PMC article. Clinical Trial.
Neoadjuvant Therapy for Resectable Pancreatic Cancer: A New Standard of Care. Pooled Data From 3 Randomized Controlled Trials.
Birrer DL, Golcher H, Casadei R, Haile SR, Fritsch R, Hussung S, Brunner TB, Fietkau R, Meyer T, Grützmann R, Merkel S, Ricci C, Ingaldi C, Di Marco M, Guido A, Serra C, Minni F, Pestalozzi B, Petrowsky H, DeOliveira M, Bechstein WO, Bruns CJ, Oberkofler CE, Puhan M, Lesurtel M, Heinrich S, Clavien PA. Birrer DL, et al. Among authors: pestalozzi b. Ann Surg. 2021 Nov 1;274(5):713-720. doi: 10.1097/SLA.0000000000005126. Ann Surg. 2021. PMID: 34334656 Review.
Development of OXY111A, a novel hypoxia-modifier as a potential antitumor agent in patients with hepato-pancreato-biliary neoplasms - Protocol of a first Ib/IIa clinical trial.
Limani P, Linecker M, Kron P, Samaras P, Pestalozzi B, Stupp R, Jetter A, Dutkowski P, Müllhaupt B, Schlegel A, Nicolau C, Lehn JM, Petrowsky H, Humar B, Graf R, Clavien PA. Limani P, et al. Among authors: pestalozzi b. BMC Cancer. 2016 Oct 19;16(1):812. doi: 10.1186/s12885-016-2855-3. BMC Cancer. 2016. PMID: 27756258 Free PMC article. Clinical Trial.
Combination of HAI-FUDR and Systemic Gemcitabine and Cisplatin in Unresectable Cholangiocarcinoma: A Dose Finding Single Center Study.
Pietge H, Sánchez-Velázquez P, Akhoundova D, Siebenhüner A, Winder T, Bachmann H, Nguyen-Kim TDL, Breitenstein S, Knuth A, Petrowsky H, Pestalozzi B, Clavien PA, Samaras P. Pietge H, et al. Among authors: pestalozzi b. Oncology. 2021;99(5):300-309. doi: 10.1159/000512967. Epub 2021 Mar 3. Oncology. 2021. PMID: 33657549 Free PMC article. Clinical Trial.
156 results